U.S. Imposes Tariffs on Drugs, Furniture, and Lumber Amid Trade Tensions
Drug stocks are rallying as President Trump's proposed 100% tariff on branded pharmaceutical imports mainly affects companies without U.S. manufacturing, leaving most Big Pharma and generics unaffected. The tariffs highlight supply chain vulnerabilities and long-term national security concerns, especially dependence on foreign countries like China for generics, but could also hinder biotech innovation and complicate import processes.